MedPath

Paracetamol Vs Caffeine Vs Codeine in the Management of Post Traumatic Pain in Emergencies

Phase 3
Completed
Conditions
Acute Pain Due to Trauma
Interventions
Registration Number
NCT05229965
Lead Sponsor
University of Monastir
Brief Summary

The purpose of this study is to:

Compare the effect of paracetamol alone against Paracetamol+Codeine association against the association of paracetamol + Cafeine in the treatment of post-traumatic acute pain of the limbs.

Detailed Description

At admission to the emergency department, patients with acute post-traumatic pain will be included, regardless of their initial NRS .These patients will receive the necessary care for their injury (icing, reduction, immobilization, local care, sutures), then went home with a medical prescription and an outpatient appointment .

At discharge and after obtaining their signed consent . All patients included will be randomized according to a numerical randomization table ( assigned in a 1:1:1 ratio) into 3 groups ( As a treatment for their post traumatic pain at discharge for 7 days ) :

* Group 1: Paracetamol group who will receive paracetamol ( 1000 mg) : one pill 3 times a day for 7 days .

* Group 2: Paracetamol-codeine group who will receive an association of 500 mg of Paracetamol and 30 mg of codeine : one pill twice a day for 7 days .

* Group 3: Paracetamol-cafeine group who will receive an association of 500 mg of Paracetamol and 65 mg of cafeine : one pill 3 times a day for 7 days .

For all patients included in the study, demographic and clinical data will be collected by the physician or investigator and recorded on a pre-established form.

The demographic data recorded on each patient's chart were as follows: Age, sex, origin and personal pathological history:

* Hypertension.

* Diabetes.

* Respiratory insufficiency.

* Renal insufficiency.

* Liver failure.

* Allergy.

And a Clinical examination data:

* Pain intensity (NRS).

* Mechanism of trauma and site of injury.

* Other physical examination data: systolic blood pressure (SBP), heart rate (HR) and temperature.

* Nature of traumatic injury.

* Final diagnosis

* Injury Severity Score (ISS).

* NRS at discharge (at rest and on movement).

Patients included will be assessed at Day 1 , Day 2 , Day 3 and Day 7 after discharge from the emergency department by a telephone call. This evaluation will include :

* NRS at rest and during movement

* Secondary use of another analgesic.

* Patient satisfaction assessed by Likert scale, with 3 responses:

* Satisfied

* Moderately satisfied

* Not satisfied

* Side effects: epigastralgia, dizziness, somnolence, headache, nausea and/or vomiting, insomnia, constipation, palpitation, etc.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1500
Inclusion Criteria
  • Age :18 years or older
  • Patients presented to the emergency department with acute post-traumatic pain and residual pain at rest and/or on movement with a numerical pain rating scale (NRS) > 3/10 on discharge.
  • They all signed a written consent form.

Exclusion criteria:

  • Self-mutilation
  • Severe acute trauma that may require hospitalization
  • Open or complicated fracture requiring surgical management
  • Regular use of analgesics
  • Any known allergy to paracetamol, caffeine or codeine
  • Asthma and acute/chronic respiratory insufficiency
  • Severe renal insufficiency (creatinine Cl<30 ml/min)
  • Pregnant/lactating women
  • Hepatic cirrhosis.
  • Refusal, incapacity or difficulties to consent or to communicate
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Paracétamol Codéine GroupParacetamol CodeineIn each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) . In Paracetamol codéine group , the patients will receive a pill containing an association of paracetamol and codéine ( 500mg / 30mg ) 3 times a day for 7 days . -Association of Paracétamol and Codéine ( 500mg / 30 mg) : 1 pill \*2 /day
Paracétamol Caféine GroupParacetamol caféineIn each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) . In Paracetamol caféine group , the patients will receive a pill containing an association of paracetamol and caféine ( 500mg / 65 mg ) 3 times a day for 7 days . -Association of Paracétamol and Caféine ( 500mg / 65 mg) : 1 pill \*3 /day
Paracétamol GroupParacetamolIn each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracétamol Caféine Group) . In Paracetamol group , the patients will receive a pill containing 1000 mg of paracetamol 3 times a day for 7 days . Paracétamol 1000 mg : 1 pill \*3 / day
Primary Outcome Measures
NameTimeMethod
Delta Numerical Rating Scale (NRS) ( From 0 to 10 )7 days from discharge

Treatment success is defined by the percentage of patients with a reduction in movement NRS at Day 7 discharge (Delta NRS ) ≥ 50% compared with NRS at emergency discharge. ( that mean a better outcome )

Delta NRS ( in movement)=(NRS (at discharge )-NRS (day7))/(NRS (at discharge )) X 100 .

Secondary Outcome Measures
NameTimeMethod
Need for another analgesic medication or non-pharmacological analgesic intervention7 days from discharge

The patient's need to add another analgesic medication or non-pharmacological analgesic intervention

Patient satisfaction assessed by Likert's verbal scale at 7 days7 days from discharge

patient satisfaction assessed by Likert's verbal scale : with 3 responses:

* Satisfied

* Moderately satisfied

* Not satisfied

Appearance of side effects7 days from discharge

The appearance of side effects such as Drowsiness ,Decreased respiratory rate (\<14 c / min), Cutaneous rash, Vomiting,Nausea,pruritus, Dizziness and Digestive hemorrhage.

Trial Locations

Locations (1)

Nouira Semir

🇹🇳

Monastir, Tunisia

© Copyright 2025. All Rights Reserved by MedPath